Lon Juricic Highlights the Following Stocks: Carrington Labs, Healthcare Technologies, IOMED, Seattle Genetics, ArQule, and Microsoft.

Business Editors

CHICAGO--(BUSINESS WIRE)--Sept. 5, 2003

Let Lon Juricic be your guide as you go inside the ever-evolving biotechnology space with one of this pro`s new recommendations and updates on current positions. Read about Carrington Laboratories, Inc. (NASDAQ:CARN), Healthcare Technologies (NASDAQ:HCTL), IOMED, Inc. (AMEX:IOX), Seattle Genetics, Inc. (NASDAQ:SGEN), ArQule, Inc. (NASDAQ:ARQL), and Microsoft (NASDAQ:MSFT). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/

Here are the highlights from the Featured Expert column:

It was another exciting few weeks for Lon Juricic's portfolio. On August 27th, he closed positions in two of his portfolio stocks after their price targets were met. Carrington Laboratories, Inc. (NASDAQ:CARN) was closed with a 111% gain and Healthcare Technologies (NASDAQ:HCTL) was closed with a 100% gain.

New Positions

IOMED, Inc. (AMEX:IOX) is engaged in the development, manufacture and sale of active drug transport systems primarily used to treat acute local inflammation in the sports and occupational medicine and physical therapy markets. Early on September 3rd, the company reported fiscal net income of $785,000, or $0.10 per diluted share, compared to a net loss of $2,362,000 or $0.36 per share, for fiscal 2002. Total revenues for fiscal 2003 came in at $12,107,000 compared with $11,760,000 a year ago. The company has cash and cash equivalents of nearly $6 million and generated record operating cash flow for fiscal 2003 of $1.7 million.

Updated Positions

Seattle Genetics, Inc. (NASDAQ:SGEN) discovers and develops monoclonal antibody-based drugs to treat cancer and other human diseases. The Company's product candidates encompass three technologies: genetically engineered monoclonal antibodies, monoclonal antibody-drug conjugates (ADCs) and antibody-directed enzyme prodrug therapy (ADEPT). Paul Allen sold about half his stake in SGEN since Juricic's last update and the stock has been moving higher ever since. Even without the support of the former Microsoft (NASDAQ: MSFT) exec, Juricic is still very excited about SGEN. The momentum just keeps building and the positive news on their cancer treatments has him excited to see the trial results.

ArQule, Inc. (NASDAQ:ARQL) is a recognized leader in small-molecule chemistry, and is pursuing a strategy to become an efficient drug discovery and development company. ArQule provides high quality library design and compound production to pharmaceutical Collaborators. On July 17th ARQL acquired privately held, cancer therapeutics company, Cyclis Pharmaceuticals. Cyclis is discovering and developing small-molecule cancer drugs based on a novel technology designed to selectively kill cancer cells and preserve normal cells by restoring and activating cellular checkpoints known to be defective in cancers. Although the stock has been stagnating since Juricic's first recommendation, the recent positive developments at ARQL gives him confidence in the future of the company.

Get plenty more information on the above-mentioned companies, including their price targets, and make sure to study all of Lon Juricic's positions by clicking: http://featuredexpert3bw.zacks.com/

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.